Moomoo AI 已提取核心信息
Arcutis Biotherapeutics, a biopharmaceutical company, has been informed by the United States Securities and Exchange Commission (SEC) that its Registration Statement on Form S-3, filed on January 31, 2024, will not undergo review by the commission. The SEC's communication, addressed to Todd Franklin Watanabe, the President and CEO of Arcutis, was dated February 5, 2024. The SEC also reminded the company of its responsibility for the accuracy and adequacy of its disclosures, irrespective of the SEC's review process. The SEC provided contact information for any further questions and copied Ross McAloon on the correspondence.
Arcutis Biotherapeutics, a biopharmaceutical company, has been informed by the United States Securities and Exchange Commission (SEC) that its Registration Statement on Form S-3, filed on January 31, 2024, will not undergo review by the commission. The SEC's communication, addressed to Todd Franklin Watanabe, the President and CEO of Arcutis, was dated February 5, 2024. The SEC also reminded the company of its responsibility for the accuracy and adequacy of its disclosures, irrespective of the SEC's review process. The SEC provided contact information for any further questions and copied Ross McAloon on the correspondence.
美国证券交易委员会（SEC）已告知生物制药公司Arcutis Biotherapeutics，其于2024年1月31日提交的S-3表格注册声明将不接受该委员会的审查。美国证券交易委员会致Arcutis总裁兼首席执行官渡边托德·富兰克林的信函日期为2024年2月5日。美国证券交易委员会还提醒该公司，无论美国证券交易委员会的审查程序如何，其披露的准确性和充分性都有责任。美国证券交易委员会为任何其他问题提供了联系信息，并在信函中复制了罗斯·麦卡隆。
美国证券交易委员会（SEC）已告知生物制药公司Arcutis Biotherapeutics，其于2024年1月31日提交的S-3表格注册声明将不接受该委员会的审查。美国证券交易委员会致Arcutis总裁兼首席执行官渡边托德·富兰克林的信函日期为2024年2月5日。美国证券交易委员会还提醒该公司，无论美国证券交易委员会的审查程序如何，其披露的准确性和充分性都有责任。美国证券交易委员会为任何其他问题提供了联系信息，并在信函中复制了罗斯·麦卡隆。
有用
没用